Literature DB >> 27346274

Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Taichi Nakamura1, Irene Ramos-Álvarez1, Tatiana Iordanskaia1, Paola Moreno1, Samuel A Mantey1, R T Jensen2.   

Abstract

Bombesin-receptor-subtype-3 (BB3 receptor) is a G-protein-coupled-orphan-receptor classified in the mammalian Bombesin-family because of high homology to gastrin-releasing peptide (BB2 receptor)/neuromedin-B receptors (BB1 receptor). There is increased interest in BB3 receptor because studies primarily from knockout-mice suggest it plays roles in energy/glucose metabolism, insulin-secretion, as well as motility and tumor-growth. Investigations into its roles in physiological/pathophysiological processes are limited because of lack of selective ligands. Recently, a selective, peptide-antagonist, Bantag-1, was described. However, because BB3 receptor has low-affinity for all natural, Bn-related peptides, little is known of the molecular basis of its high-affinity/selectivity. This was systematically investigated in this study for Bantag-1 using a chimeric-approach making both Bantag-1 loss-/gain-of-affinity-chimeras, by exchanging extracellular (EC) domains of BB3/BB2 receptor, and using site-directed-mutagenesis. Receptors were transiently expressed and affinities determined by binding studies. Bantag-1 had >5000-fold selectivity for BB3 receptor over BB2/BB1 receptors and substitution of the first EC-domain (EC1) in loss-/gain-of affinity-chimeras greatly affected affinity. Mutagenesis of each amino acid difference in EC1 between BB3 receptor/BB2 receptor showed replacement of His(107) in BB3 receptor by Lys(107) (H107K-BB3 receptor-mutant) from BB2 receptor, decreased affinity 60-fold, and three replacements [H107K, E11D, G112R] decreased affinity 500-fold. Mutagenesis in EC1's surrounding transmembrane-regions (TMs) demonstrated TM2 differences were not important, but R127Q in TM3 alone decreased affinity 400-fold. Additional mutants in EC1/TM3 explored the molecular basis for these changes demonstrated in EC1, particularly important is the presence of aromatic-interactions by His(107), rather than hydrogen-bonding or charge-charge interactions, for determining Bantag-1 high affinity/selectivity. In regard to Arg(127) in TM3, both hydrogen-bonding and charge-charge interactions contribute to the high-affinity/selectivity for Bantag-1. Published by Elsevier Inc.

Entities:  

Keywords:  Bombesin; Gastrin-releasing peptide; Neuromedin B; Obesity; Satiety

Mesh:

Substances:

Year:  2016        PMID: 27346274      PMCID: PMC4980153          DOI: 10.1016/j.bcp.2016.06.013

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  80 in total

1.  Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Authors:  Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2010-05-12       Impact factor: 3.750

Review 2.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

3.  Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example.

Authors:  Taichi Nakamura; Hisato Igarashi; Tetsuhide Ito; Robert T Jensen
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

4.  Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor.

Authors:  K Tokita; T Katsuno; S J Hocart; D H Coy; M Llinares; J Martinez; R T Jensen
Journal:  J Biol Chem       Date:  2001-08-02       Impact factor: 5.157

5.  Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3.

Authors:  S A Mantey; D H Coy; T K Pradhan; H Igarashi; I M Rizo; L Shen; W Hou; S J Hocart; R T Jensen
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

Review 6.  Opioid receptors: Structural and mechanistic insights into pharmacology and signaling.

Authors:  Yi Shang; Marta Filizola
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

7.  Molecular basis of the selectivity of gastrin-releasing peptide receptor for gastrin-releasing peptide.

Authors:  Kenji Tokita; Simon J Hocart; David H Coy; Robert T Jensen
Journal:  Mol Pharmacol       Date:  2002-06       Impact factor: 4.436

8.  Delineation of a region in the B2 bradykinin receptor that is essential for high-affinity agonist binding.

Authors:  J Nardone; P G Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  Contribution of melanocortin receptor exoloops to Agouti-related protein binding.

Authors:  Y K Yang; C J Dickinson; Q Zeng; J Y Li; D A Thompson; I Gantz
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

10.  The multiple roles of histidine in protein interactions.

Authors:  Si-Ming Liao; Qi-Shi Du; Jian-Zong Meng; Zong-Wen Pang; Ri-Bo Huang
Journal:  Chem Cent J       Date:  2013-03-01       Impact factor: 4.215

View more
  6 in total

Review 1.  Understanding Peptide Binding in Class A G Protein-Coupled Receptors.

Authors:  Irina G Tikhonova; Veronique Gigoux; Daniel Fourmy
Journal:  Mol Pharmacol       Date:  2019-07-10       Impact factor: 4.436

2.  Development and Characterization of a Novel, High-Affinity, Specific, Radiolabeled Ligand for BRS-3 Receptors.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

Review 3.  Peptide receptors as cancer drug targets.

Authors:  Terry W Moody
Journal:  Ann N Y Acad Sci       Date:  2019-05-10       Impact factor: 5.691

4.  The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3.

Authors:  Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2022-05-29       Impact factor: 4.402

5.  AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists.

Authors:  Terry W Moody; Nicole Tashakkori; Samuel A Mantey; Paola Moreno; Irene Ramos-Alvarez; Marcello Leopoldo; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-21       Impact factor: 5.555

Review 6.  Neuropeptide G Protein-Coupled Receptors as Oncotargets.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-29       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.